Sonorepro™ by pixie dust technologies, inc. featured in medical practice and new drugs 2023 study

New study showcases efficacy of sonorepro™ new york and tokyo , dec. 14, 2023 /prnewswire/ - pixie dust technologies, inc. (nasdaq: pxdt) (the " company"), a japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that a company-sponsored experiment on the company's sonorepro™ product was recently conducted by dr. akinobu miyata, director of miyata medical clinic, in collaboration with the japan clinical trial association (jacta). the study, aimed at determining the effects on the scalp and hair when using sonorepro™ with scalp lotion for 12 weeks, consisted of adult men and women under 49 years old who were concerned about thinning hair.
PXDT Ratings Summary
PXDT Quant Ranking